Hager Bio engineered and developed a first in class novel small molecule discovery platform that successfully enables modulations of pharmacological targets that are on complimentary central nervous system network signaling axis. Through simultaneous and rationale modulations of multiple signaling pathways that play critical functional roles in diseases, our molecules are designed to produce better efficacy with minimal side effects. First in class, our several diverse and highly efficacious novel molecules are at various stages of development including safety assessments, directed as therapeutics for currently unmet neuropsychiatric and neurological indications.